A Phase 1, Single Center Double-blind, Randomized, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Omecamtiv Mecarbil in Healthy Japanese Subjects
Phase of Trial: Phase I
Latest Information Update: 12 Feb 2016
At a glance
- Drugs Omecamtiv mecarbil (Primary)
- Indications Acute heart failure; Chronic heart failure
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Amgen
- 27 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 25 Nov 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 14 Nov 2015 New trial record